Tirzepatide vs. Semaglutide

Back to Blog

The Fundamental Difference: Single vs. Dual Receptor

At the molecular level, the choice between Semaglutide and Tirzepatide comes down to one key distinction: how many hormone receptors the drug activates.

Think of it this way: Semaglutide attacks obesity through one highly effective pathway. Tirzepatide attacks it through two, which in clinical trials has translated to greater average weight loss.

---

Head-to-Head: Clinical Trial Data

While no single trial has directly compared identical populations on both drugs simultaneously at their maximum weight-loss doses, the landmark trials provide robust cross-comparison data:

Semaglutide: The STEP Trials

• STEP 1: 1,961 adults without diabetes. Average weight loss: 14.9% at 2.4 mg over 68 weeks
• STEP 3: Combined with intensive behavioral therapy: 16.0% weight loss
• STEP 5: Two-year data: 15.2% sustained weight loss at 104 weeks
• Key stat: 86.4% of patients lost ≥5% of body weight; 32% lost ≥20%

Tirzepatide: The SURMOUNT Trials

• SURMOUNT-1: 2,539 adults without diabetes. Average weight loss at highest dose (15 mg): 22.5% over 72 weeks
• SURMOUNT-2: Adults with Type 2 diabetes: 14.7% weight loss (notably higher than diabetes-focused semaglutide trials)
• SURMOUNT-3: Combined with intensive lifestyle intervention: 26.6% weight loss
• Key stat: 63% of patients on the highest dose lost ≥20% of body weight — nearly double the rate of Semaglutide

---

Complete Side-by-Side Comparison

---

Side Effects: How Do They Compare?

Both medications share a similar side effect profile because they both activate the GLP-1 receptor. The side effects are predominantly gastrointestinal and are most common during the titration phase:

Shared Side Effects

• Nausea: The most commonly reported side effect for both. Semaglutide reports ~44% incidence; Tirzepatide is somewhat lower at ~25–33%, likely because GIP receptor activation partially counteracts GLP-1-induced nausea
• Diarrhea: ~30% for Semaglutide, ~17–23% for Tirzepatide
• Constipation: ~24% for Semaglutide, ~12–18% for Tirzepatide
• Injection site reactions: Mild redness or itching, rare for both

Key Differences

Tirzepatide generally has a lower rate of GI side effects than Semaglutide in clinical trials. This is a clinically meaningful distinction: the GIP receptor activation appears to partially offset the nausea-inducing effects of GLP-1 stimulation. For patients who discontinued Semaglutide due to intractable nausea, Tirzepatide is worth considering as an alternative.

Both medications carry the same boxed warning regarding medullary thyroid carcinoma (MTC) risk. Neither should be used by patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

---

Which One Should You Choose?

There is no universal "better" option — the right choice depends on your clinical profile, goals, and how your body responds. Here's a decision framework:

Consider Semaglutide If:

• You want a medication with 4+ years of real-world safety data and the most extensively studied weight loss profile
• You're looking for the most affordable entry point — compounded Semaglutide through Losing Weight RX starts at $146/mo flat
• You're new to GLP-1 therapy and want to start with the established standard of care
• You have Type 2 diabetes and want a medication with a long track record in both diabetes and obesity

Consider Tirzepatide If:

• You want the maximum possible weight loss — Tirzepatide's dual mechanism produces roughly 50% greater average weight loss than Semaglutide
• You tried Semaglutide and plateaued — switching to the dual agonist can restart weight loss by activating a new receptor pathway
• You experienced significant nausea on Semaglutide — Tirzepatide's GIP activation may produce fewer GI side effects for your body
• You have significant insulin resistance — the GIP receptor plays a key role in insulin sensitivity, and Tirzepatide may provide enhanced metabolic correction

Can You Switch Between Them?

Yes — and it's more common than you'd think. There are two common switching scenarios:

Semaglutide → Tirzepatide

This is the most common switch. Patients who have plateaued on Semaglutide after significant initial weight loss may benefit from Tirzepatide's dual mechanism to unlock additional weight loss. Your provider will typically start Tirzepatide at 2.5 mg or 5 mg (depending on your current Semaglutide dose) and titrate from there.

Tirzepatide → Semaglutide

Less common, but some patients who experience side effects specific to the GIP receptor — or who have reached their goal weight and want to maintain on a lower-cost medication — may transition to Semaglutide for long-term maintenance. The transition is straightforward under provider guidance.

In both cases, there is no washout period required. Your provider will map your current dose to the appropriate starting dose on the new medication and monitor your response during the transition.

---

Compounded Versions: What You're Actually Getting

Through Losing Weight RX, both Semaglutide and Tirzepatide are available as compounded formulations from state-licensed U.S. compounding pharmacies. Here's what that means:

• Both contain the identical active molecule as their brand-name counterparts (Wegovy®/Ozempic® and Mounjaro®/Zepbound®)
• Compounding is legally authorized under federal 503A/503B regulations during active drug shortages
• Compounded versions are not individually FDA-approved — they are custom preparations that have not undergone the FDA's new drug approval process
• Pricing is dramatically lower: compounded Semaglutide starts at $146/mo vs. $1,300+/mo for brand-name Wegovy® at retail
• Your provider may compound with additional ingredients (like B12) based on your clinical needs
• Looking beyond single and dual agonists, next-generation clinical trials are actively evaluating triple agonists like Retatrutide and co-agonist combinations like CagriSema.

---

Frequently Asked Questions

---